At the European Society for the Study of Diabetes (EASD) Annual Meeting in Barcelona, Steve Bain discusses the major challenges in developing an oral GLP-1 receptor agonist and how was this overcome with semaglutide.
1. What were the major challenges in developing an oral GLP-1 receptor agonist and how was this overcome with semaglutide? (0:05)
2. Is the oral formulation likely to replace other injectable GLP-1 receptor agonists? (2:12)
3. What have been the key take home messages from the PIONEER clinical trial programme? (3:02)
4. How does oral semaglutide compare with other oral agents such as empagliflozin and sitagliptin? (4:44)
5. Which patients are most likely to benefit from oral semaglutide? (5:37)
Steve Bain has no conflicts of interest to declare in relation to this video.
Filmed at the Annual Meeting of the European Association of the Study of Diabetes (EASD) Barcelona, Spain 2019.
Share this Video
Related Videos In Diabetes
Andrew Boulton, IDF 2021 – Anticipated congress highlights
It was a pleasure to meet with IDF President, Prof. Andrew Boulton (University of Manchester, UK) ahead of this year’s virtual meeting to discuss anticipated congress highlights and the relationship between COVID-19 and diabetes. Questions What do you expect to be the highlights of this year’s IDF Congress? (0:20-1:30) What have we learned about the […]
IDF Virtual 2021 – Diabetes Complications and Covid-19
The International Diabetes Federation will organise a Virtual Congress on December 6-11, 2021. It will feature the latest research on diabetes complications and sessions dedicated to COVID-19 and diabetes, the centenary of insulin and the IDF Diabetes Atlas 10th Edition. Discover the Congress at https://idf2021.org
Matthew Budoff, ENDO 2021: Findings from a Substudy of the VERTIS CV Trial – Ertugliflozin for T2DM & ASCVD
We caught up with Professor Matthew Budoff (UCLA and Lundquist Institute, Torrance, CA, US) to discuss ertugliflozin in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease inadequately controlled with metformin and sulfonylurea (Clinical Trial Identifier: NCT01986881). ‘Efficacy and Safety of Ertugliflozin in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!